Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Sangamo Therapeutics (SGMO) EBIT (2016 - 2025)

Sangamo Therapeutics (SGMO) has disclosed EBIT for 16 consecutive years, with -$38.2 million as the latest value for Q4 2025.

  • For Q4 2025, EBIT fell 46.99% year-over-year to -$38.2 million; the TTM value through Dec 2025 reached -$121.2 million, down 16.61%, while the annual FY2025 figure was -$121.2 million, 16.61% down from the prior year.
  • EBIT hit -$38.2 million in Q4 2025 for Sangamo Therapeutics, down from -$35.6 million in the prior quarter.
  • Across five years, EBIT topped out at $18.0 million in Q1 2023 and bottomed at -$123.6 million in Q2 2023.
  • Average EBIT over 5 years is -$44.2 million, with a median of -$45.5 million recorded in 2022.
  • Year-over-year, EBIT plummeted 1208.73% in 2021 and then skyrocketed 139.84% in 2023.
  • Sangamo Therapeutics' EBIT stood at -$39.9 million in 2021, then plummeted by 38.83% to -$55.4 million in 2022, then dropped by 12.04% to -$62.1 million in 2023, then skyrocketed by 58.12% to -$26.0 million in 2024, then crashed by 46.99% to -$38.2 million in 2025.
  • According to Business Quant data, EBIT over the past three periods came in at -$38.2 million, -$35.6 million, and -$17.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.